Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,726 JPY | -0.19% | -3.94% | +15.64% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is not the most generous with respect to shareholders' compensation.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.64% | 1.47B | C | ||
+21.82% | 73.31B | C+ | ||
-2.32% | 23.98B | C+ | ||
+4.89% | 8.8B | C | ||
+10.52% | 8.6B | B | ||
-19.56% | 8.07B | B- | ||
+14.77% | 5.26B | B- | ||
-0.93% | 4.16B | B- | ||
+12.13% | 4.14B | B+ | ||
-2.75% | 3.88B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 8129 Stock
- Ratings Toho Holdings Co., Ltd.